Arrotek and its sister company, US-based NeedleTech, will now both trade under the Arrotek brand name. The new brand offering will have enhanced operating bases in the US and EU, as well as an extended service offering covering the design, development, and manufacture of minimally invasive medical devices.
Arrotek specialises in medical device design with a particular emphasis on interventional/diagnostic catheters and related technologies. Arrotek also has manufacturing capabilities at its facility in Sligo, Ireland, as well as regulatory expertise.
From its base in Massachusetts, USA, NeedleTech specialises in needles, cannulas, stylets, and similar medical device components.
Both companies have strong reputations and proven track records in the industry. Customers range from startups to OEMs to the largest corporations in the life sciences sector. The new brand offering will build on the foundations that currently exist in areas that include product quality and innovation.
Enhanced and Extended Services
Both brands, Arrotek and NeedleTech, are part of the Theragenics group of companies. Commenting on the announcement, Mark Pugh, Director of the OEM Group, said the new brand offering will offer an extended level of service to customers, particularly those in the US and EU.
Mark said: “I am delighted to announce Arrotek and NeedleTech will now both trade under the Arrotek brand name. This will enhance our current offering, extending the services we provide. We are also investing in our shared engineering departments to put the structures in place to take our business forward.
“I would like to take this opportunity to thank our current customers for their continued support. As a combined team, we are looking forward to enhancing the services we offer and strengthening our partnerships together.
“It’s an exciting time for this new venture, especially given the strengths of our teams across both facilities in the US and EU.
“This is also an exciting time for the medical device industry and wider healthcare sector as advances in technologies and therapeutics open the door to new and cutting-edge treatments. Patient outcomes are being transformed by these new and innovative treatments, and this is only going to accelerate.
